Literature DB >> 32456459

TNFAIP2 Promotes Non-small Cell Lung Cancer Cells and Targeted by miR-145-5p.

Jianing Li1, Yongfeng Song2, Baiquan Yu1, Yao Yu1.   

Abstract

Tumor necrosis factor-alpha (TNFα) is an inflammatory cytokine that regulates inflammation and tumor progression in non-small cell lung cancer (NSCLC). The higher levels of TNF α are known to induce expression of several genes such as TNFα-induced protein 2 (TNFAIP2) with a largely unknown role in NSCLC. We provide the preliminary evidence for the role of TNFAIP2 in NSCLC progression and its epigenetic regulation mediated by microRNA, miR-145-5p. The expression of TNFAIP2 was confirmed using quantitative real-time PCR, immunohistochemistry, and Western blot in NSCLC tissue and paired adjacent normal tissue. All in vitro assays were undertaken in A549 and H23 cells and chemoresistance assays were undertaken in A549/Cisplatin (DDP) and H23/DDP cell types. TNFAIP2 silencing was undertaken using lipofectamine transfection of specific siRNA. Cells were co-transfected with miR-145-5p, and TNFAIP2-3' untranslated region (UTR) or TNFAIP2 with mutated 3'UTR using the luciferase vector pGL. Cell viability, transwell migration, and invasion were assessed. The role of caspase 3 proteins in cell viability was ascertained using Western blot. The tumor tissues (and cisplatin-resistant cell lines A549/DDP and H23/DDP) expressed significantly higher levels of TNAIP2 mRNA and protein. Silencing of TNFAIP2 resulted in reduced cell viability, reduced invasion, and migration in vitro. Silencing of TNFAIP2 in A549/DDP and H23/DDP had higher expression of TNFAIP2, reduced cell viability, and increased induction of caspase 3. MiR-145-5p binds to the 3'UTR of TNFAIP2. Overexpression of MiR-145-5p reduced expression of TNFAIP2, decreased cell viability, reduced cell migration and invasion, and significantly reduced expression of caspase 3 protein. TNFAIP2 mediates tumorigenesis in NSCLC through, not completely known pathways. miR-145-5p negatively regulates TNFAIP2 expression. miR-145-5p-mediated therapies may be explored in NSCLC.

Entities:  

Keywords:  TNFAIP2; chemoresistance; lung cancer; miR-145-5p

Year:  2020        PMID: 32456459     DOI: 10.1089/dna.2020.5415

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Single-Molecule RNA Sequencing Reveals IFNγ-Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus-Positive MCC Cell Lines.

Authors:  Tatjana Sauerer; Christopher Lischer; Adrian Weich; Carola Berking; Julio Vera; Jan Dörrie
Journal:  Front Microbiol       Date:  2021-12-22       Impact factor: 5.640

Review 2.  Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses.

Authors:  Noemi Linden; R Brad Jones
Journal:  Trends Immunol       Date:  2022-07-08       Impact factor: 19.709

3.  In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation.

Authors:  Irena Wieleba; Kamila Wojas-Krawczyk; Izabela Chmielewska; Magdalena Wójcik-Superczyńska; Paweł Krawczyk; Janusz Milanowski
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

4.  Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation.

Authors:  Jiali An; Dingkun Hou; Lei Wang; Lili Wang; Yuanyuan Yang; Haitao Wang
Journal:  Histol Histopathol       Date:  2022-02-07       Impact factor: 2.130

Review 5.  Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.

Authors:  Yu-Gui Zhang; Jiang-Tao Niu; Hong-Wei Wu; Xin-Lei Si; Shu-Juan Zhang; Dong-Hui Li; Tian-Tian Bian; Yue-Feng Li; Xing-Ke Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2021-06-05       Impact factor: 2.916

6.  miR-145-5p inhibits the proliferation of glioma stem cells by targeting translationally controlled tumor protein.

Authors:  Qiujian Zhang; Zhe Cheng; Lei Shi; Gengsheng Mao
Journal:  J Cancer       Date:  2022-02-28       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.